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Abstract
Objective: Patients with bladder cancer have responded poorly to oxalipla-
tin therapy in clinical trials. Blockade of receptor tyrosine kinases is consid-
ered a good strategy in cancer therapy. Our previous studies have 
demonstrated the crucial roles of brain-derived neurotrophic factor and its 
receptor tropomyosin receptor kinase B (TrkB) in transitional cell carcinoma 
(TCC). The aim of this study was to examine the cytotoxic effects of lestau-
rtinib, a new pan-Trk inhibitor, and oxaliplatin on bladder cancer cell lines.
Materials and Methods: BFTC905 and T24 TCC cell lines were used for 
investigation in vitro. The effects of oxaliplatin and/or lestaurtinib on cell 
viability, apoptosis, and expression of survivin and securin were assessed. 
MTT assay was used for cytotoxic evaluation. DNA fragments were detected in 
both the culture medium and cytoplasm to differentiate the types of cell 
death (apoptosis vs. necrosis). Western blots were used to analyze the expres-
sion of survivin and securin after oxaliplatin and/or lestaurtinib treatment.
Results: Oxaliplatin at 3 μg/mL elicited cytotoxicity on BFTC905 but not 
T24 cells 48 hours after treatment. The addition of 1 or 3 μM lestaurtinib 
to oxaliplatin did not exert additive cytotoxic effects on BFTC905 cells. 
Although oxaliplatin at 3 μg/mL had no effect on T24 cells, the addition of 
1 or 3 μM lestaurtinib demonstrated concentration-dependent inhibitory 
effects. Apoptosis of T24 cells was observed after treatment with lestau-
rtinib alone and lestaurtinib plus oxaliplatin. Furthermore, in T24 cells, the 
expression of survivin was inhibited by a combination of lestaurtinib and 
oxaliplatin, while securin expression was inhibited by lestaurtinib alone 
and lestaurtinib with oxaliplatin.
Conclusion: Lestaurtinib may be a potential new drug for the targeted 
therapy of oxaliplatin-resistant TCC. Further in vivo studies are needed. 
[Tzu Chi Med J 2010;22(3):125–130]
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1. Introduction
The distribution of urinary bladder cancer varies sig-
nificantly between geographical regions and coun-
tries. The incidence is much higher in developed 
countries and some areas such as North America 
and Western Europe [1]. In Taiwan, the Bureau of 
Health Promotion, Department of Health reported that 
it was the eighth most common malignancy in 2007 
with 1,457 new cases. Pathological classification indi-
cates that more than 90% of bladder cancers are 
transitional cell carcinoma (TCC) [2]. Once distant me-
tastasis occurs, the median survival is approximately 
1 year even after aggressive treatment [3]. Therefore, 
we need to investigate new strategies and more ef-
fective treatments for metastatic bladder cancer.
Some receptor tyrosine kinases (RTKs) that are 
overexpressed in cancer tissues have been charac-
terized as oncogenes. Thus, RTK blockade is currently 
considered a good strategy for clinical cancer therapy, 
especially for inoperable conditions [4]. Over expression 
of some growth factors and their specific RTKs have 
been found in bladder cancer, including epidermal 
growth factor receptor, platelet-derived growth factor 
receptor β, and fibroblast growth factor 3, and have 
been correlated with poor clinical outcomes [5]. How-
e ver, there have been only a few clinical trials of targeted 
therapy for bladder cancer because some preclinical 
trials of targeted therapies on certain RTKs showed 
disappointing results [5]. Thus, new RTKs should be 
investigated for targeted therapy of bladder cancer.
The tropomyosin receptor kinase (Trk) family of 
tyrosine kinase receptors consists of TrkA, TrkB and 
TrkC. These Trk receptors and their ligands play impor-
tant roles in neuronal survival and differentiation [6]. 
TrkB and/or its ligand, brain-derived neurotrophic fac-
tor (BDNF), have also been found in solid malignancies 
such as pancreatic ductal adenocarcinoma [7], pros-
tate cancer [8], and lung cancer [9]. In our previous re-
ports, BDNF and TrkB, but not TrkA or TrkC, were found 
in three TCC cell lines, BFTC905, TSGH8301, and T24 
[10]. Increased immunostaining for BDNF and TrkB was 
observed in human TCC specimens compared to nor-
mal tissues [11]. The proliferation and invasiveness of 
BFTC905 cells were enhanced by BDNF. TrkB antibody 
suppressed proliferation, elicited cytotoxicity, and in-
hibited migration [12]. These results indicate that both 
BDNF and TrkB play important roles in the progres-
sion of TCC. Drugs aimed at BDNF or TrkB receptors 
may provide a new potential approach for treating TCC.
Lestaurtinib (CEP-701) has been approved by the 
U.S. Food and Drug Administration for acute myeloid 
leukemia because of its potent inhibition of FMS-like 
tyrosine kinase 3 (also a member of the type III TRK 
superfamily) with an IC50 of 3 nM [13,14]. Lestaurtinib 
also inhibits the phosphorylation of TrkA and TrkB 
[15] as well as the tumor growth of pancreatic ductal 
adenocarcinoma xenografts through Trk blockade 
[16,17]. We hypothesize that lestaurtinib could elicit 
cytotoxicity and induce apoptosis in TCC cells in vitro 
and be a potential new drug for the targeted therapy 
of bladder cancer.
2. Materials and methods
2.1. Cell culture
Human TCC cell lines, BFTC905 and T24, were used 
for the study. The cells were maintained as described 
previously [10]. Gradings of BFTC905 [18] (originat-
ing from Taiwanese patients with TCC) and T24 (from 
ATCC, American Type Culture Collection, Manassas, 
VA, USA) were 3 and 2/3, respectively.
2.2. MTT cytotoxicity assay
For the cytotoxicity assay, 1 × 104 TCC cells per well 
were seeded in 96-well plates. After incubation over-
night, the cells adhered on the plate. Lestaurtinib 
(LC Laboratories, Woburn, MA, USA), 1 or 3 μM, dis-
solved in 45% γ-cyclodextrin (Sigma, St. Louis, MO, 
USA) and oxaliplatin (Sanofi-Aventis, Paris, France) 
3 μg/mL dissolved in phosphate-buffered saline (PBS) 
were administrated for 48 hours. The same volume of 
γ-cyclodextrin or PBS treatment served as a negative 
control. Conventional MTT (methylthiazolyldiphenyl-
tetrazolium bromide; Sigma) assay was followed using 
the standard protocol [10].
2.3. DNA fragment assay
The apoptotic or necrotic condition of TCC cells after 
drug treatments was assessed by cell death detec-
tion ELISAplus (Roche, Mannheim, Germany). Forty-
eight hours after treatment with oxaliplatin and/or 
lestaurtinib, the supernatants of both the culture 
medium and the cytoplasmic fraction of 2 × 104 TCC 
cells in 24-well dishes were used. The O.D. value at 
405 nm, representing the extent of DNA fragmenta-
tion, was measured by an ELISA reader.
2.4. Western blot
Standard procedures were followed as previously de-
scribed [10]. Primary antibodies used were anti-survivin 
(#2808; Cell Signaling Technology Inc., Danvers, MA, 
USA) and anti-securin (ab3305; Abcam Inc., Cambridge, 
MA, USA). Expression of α-tubulin (sc-8305; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) was used as 
the internal standard. The intensity of immunoreactive 
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proteins was calculated using National Institutes of 
Health software ImageJ version 1.40. The intensity 
ratio was the intensity of survivin or securin divided 
by that of α-tubulin, and was used to compare the 
drug effects.
2.5. Statistical analysis
Data are expressed as mean ± standard error of the 
mean, and were evaluated by Student’s t test. In all 
cases, p < 0.05 was considered statistically significant.
3. Results
3.1. Cytotoxicity of oxaliplatin alone or 
in combination with lestaurtinib on 
BFTC905 and T24 cells
As shown in Fig. 1, oxaliplatin at 3 μg/mL inhibited 
33% of BFTC905 cell viability (66.7 ± 9.6% of viability 
compared to PBS control; n = 3) 48 hours after treat-
ment. However, 3 μg/mL of oxaliplatin did not exert 
significant cytotoxicity on T24 cells (96.4 ± 5.8% of 
viability compared to PBS control; p = 0.33, n = 3).
A combination of oxaliplatin and lestaurtinib 
showed no additive cytotoxic effects on BFTC905 
cells (62.8 ± 3.1% and 62.8 ± 6.3% of viability, after 
treatment with 1 and 3 μM lestaurtinib plus 3 μg/mL 
oxaliplatin, respectively; n = 3). In contrast, 1 and 3 μM 
lestaurtinib when combined with 3 μg/mL oxaliplatin 
concentration-dependently inhibited the viability of 
T24 cells (57.3 ± 2.7% and 34.2 ± 1.2% of viability 
after treatment with 1 and 3 μM lestaurtinib plus 
3 μg/mL oxaliplatin, respectively; n = 3).
3.2. Lestaurtinib induced apoptosis in
T24 cells
To determine the characteristics of cytotoxicity medi-
ated by lestaurtinib on T24 cells, DNA fragment ELISA 
assay was carried out (Fig. 2). Low basal level DNA 
fragments bound by anti-histone and anti-DNA anti-
bodies in the ELISA assay kit were detected in the 
culture medium of T24 cells after lestaurtinib and/or 
oxaliplatin treatment. However, a large amount of 
cytoplasmic DNA fragments was observed after treating 
T24 cells with 1 μM lestaurtinib alone or in combination 
with 3 μg/mL oxaliplatin when compared with treatment 
with 3 μg/mL oxaliplatin alone (p = 0.000001 and 
0.00002, respectively; n = 3). A small amount of cyto-
plasmic DNA fragments was detected in the control 
and oxaliplatin-treated cytoplasmic samples (p = 0.33, 
n = 3). These results indicated that lestaurtinib but 
not oxaliplatin induced apoptosis of T24 cells.
3.3. Expression of survivin and securin in 
T24 cells after lestaurtinib treatment
Decreased expression of survivin in bladder cancer 
specimens has been reported to be a good predictor 
Fig. 1 — Cytotoxic effects of oxaliplatin alone and in com-
bination with lestaurtinib on BFTC905 and T24 cells. The 
viability of (A) BFTC905 and (B) T24 cells was measured 
by MTT assay 48 hours after treatment with 3 mg/mL oxali-
platin or 3 mg/mL oxaliplatin plus 1 or 3 mM lestaurtinib. 
The viability ratio was the ratio of the O.D. value from the 
drug-treated sample divided by that of the control sample. 
*p < 0.05.
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Fig. 2 — DNA fragments in the culture medium or cyto-
plasm of T24 cells detected by ELISA. Forty-eight hours 
after treatment with oxaliplatin and/or lestaurtinib, the 
supernatants of both the culture medium and the cyto-
plasmic fraction of 2 × 104 transitional cell carcinoma cells 
were collected. Increased expression of DNA fragments in 
the medium indicates necrosis due to membrane rupture, 
while increased expression in the cytoplasm alone indi-
cates apoptosis. *p < 0.05.
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of response to therapy [19,20]. Securin, also called 
pituitary tumor-transforming gene, plays important 
roles in tumorigenesis and invasiveness in various 
neoplasms [21]. As shown in Fig. 3, survivin expres-
sion in T24 cells was not altered 48 hours after treat-
ment with lestaurtinib (1 μM) or oxaliplatin (3 μg/mL), 
but was almost completely inhibited when treated with 
a combination of lestaurtinib and oxaliplatin. Ox-
aliplatin at 3 μg/mL alone had no effect on securin 
expression. Lestaurtinib at 1 μM markedly inhibited 
the expression of securin, but there was no further 
inhibition when combined with oxaliplatin (Fig. 4).
4. Discussion
Oxaliplatin is a third-generation platinum derivative 
with a 1,2-diamino-cyclohexane carrier ligand. It has 
less renal toxicity than cisplatin, but is at least equally 
as cytotoxic as cisplatin on cancer cells. Many cisplatin-
resistant cancer cell lines are sensitive to oxaliplatin 
because it demonstrates multiple mechanisms of ac-
tion [22]. The present study suggests that oxaliplatin 
could be an alternative agent for bladder cancer treat-
ment. However, a disappointing response rate was 
observed in patients with previously treated, unre-
sectable or metastatic TCC [23]. In two recent phase 
II trials, a combination of oxaliplatin and gemcitabine 
showed a satisfactory overall response rate (47–48%) 
in patients with locally advanced or metastatic urothe-
lial cancer [24,25]. However, the above data reflect 
that this drug combination was ineffective in half of 
the patients with TCC. In addition, the median time to 
disease progression was delayed by just 5 months 
under this combination treatment [24]. T24 cells have 
been reported to be an oxaliplatin-resistant TCC cell 
line [26]. Thus, we examined if enhanced cytotoxicity 
on TCC cells could be achieved by a combination of 
oxaliplatin plus other agents.
Oxaliplatin elicited cytotoxicity on BFTC905 but not 
T24 cells in this study. The characteristics of oxaliplatin 
resistance in T24 cells are consistent with a previous 
report [26]. Several mechanisms of oxaliplatin resis-
tance, including reduced drug accumulation similar to 
that of cisplatin [27], and increased cellular glutath-
ione [28], have been reported. Uptake of oxaliplatin 
in T24 cells is apparently less than that in oxaliplatin-
sensitive testicular 833k cells [26]. Increased heat 
shock protein 60 mRNA may also be a factor of resis-
tance to platinum analogs in human ovarian and 
bladder carcinoma cell lines [29]. The mechanisms 
of differential sensitivity between T24 and BFTC905 
cells toward oxaliplatin require further investigation.
Recent strategies for cancer therapy have em-
ployed a combination of cytotoxic and targeted agents, 
but variable results have been reported in pre-clinical 
Fig. 3 — Expression of survivin after oxaliplatin and/or 
lestaurtinib treatment. (A) A representative Western blot 
of the expression of survivin examined 48 hours after 
oxaliplatin and/or lestaurtinib treatment. Expression 
of a-tubulin was used as an internal standard. (B) 
Quantitative comparison of the survivin expression in 
each group (n = 3). *p < 0.05.
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Fig. 4 — Expression of securin after oxaliplatin and/or 
lestaurtinib treatment. (A) A representative Western blot 
of the expression of securin examined 48 hours after 
oxaliplatin and/or lestaurtinib treatment. Expression of 
a-tubulin was used as an internal standard. (B) 
Quantitative comparison of the securin expression in 
each group (n = 3). *p < 0.05.
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and clinical trials [30–33]. Consequently, we assessed 
the effects of a novel combination involving lestau-
rtinib and oxaliplatin in vitro, especially in oxaliplatin-
resistant TCC cell lines. Lestaurtinib plus oxaliplatin 
elicited far more potent cytotoxicity on T24 cells 
than oxaliplatin alone, and a higher concentration of 
lestaurtinib exhibited greater cytotoxicity when com-
bined with oxaliplatin. However, lestaurtinib and les-
taurtinib plus oxaliplatin exerted similar cytotoxic 
effects on T24 cells (results not shown). In contrast, 
the cytotoxic effects on BFTC905 cells seemed to re-
sult from oxaliplatin alone. Our preliminary results 
also showed that lestaurtinib has a higher IC50 ( 5 μM) 
on BFTC905 cells than T24 cells ( 1 μM). This ob-
servation may partially explain why 3 μM lestaurtinib 
only inhibited the cell viability by 40%. The apoptosis 
and inhibition of securin expression on T24 cells after 
lestaurtinib and/or oxaliplatin treatment are consistent 
with results from the cytotoxic MTT assay. The con-
centration used in our study was within the trough 
level, between 1.1 and 13.3 μM, found on day 28 in a 
study of patients with acute myeloid leukemia who 
received 60 mg lestaurtinib twice daily [34]. These re-
sults demonstrated the potential of lestaurtinib for 
bladder cancer therapy. Combinations of lestaurtinib 
and other chemotoxic agents that exert greater cyto-
toxicity should be explored.
Survivin, a member of the inhibitor of apoptosis 
protein family, has been shown to be a promising bi-
omarker for the diagnosis and prognosis of bladder 
cancer [20,35,36]. Our results showed that neither 
oxaliplatin nor lestaurtinib altered survivin expression 
in T24 cells. However, lestaurtinib together with oxali-
platin markedly reduced the expression of survivin. 
In previous reports, downregulation of survivin by 
oxaliplatin diminished radioresistance and enhanced 
the effects of paclitaxel on head and neck squamous 
carcinoma cells in vitro [37,38]. This may explain why 
oxaliplatin administration did not alter survivin ex-
pression in oxaliplatin-resistant T24 cells. However, 
the observation that lestaurtinib did not affect sur-
vivin expression in T24 cells was not consistent with 
its cytotoxic effect and inhibition of securin expres-
sion. Our preliminary experiments also revealed that 
lestaurtinib did not change the survivin expression 
in BFTC905 cells. Recently, we have shown that block-
ade of TrkB by its specific TrkB antibody inhibited 
survivin expression on these TCC cells [12]. There 
might be compensatory mechanisms to restore the 
expression of survivin, which is inhibited by lestau-
rtinib beyond its TrkB blocking effect.
Securin expressed in nuclei was originally demon-
strated as an inhibitor of premature sister chromatid 
separation as well as a potential activator of transcrip-
tion, but recently it has also been proved to mediate 
tumor invasiveness and recurrence [21]. One example 
is that overexpressed securin in glioma specimens is 
associated with an unfavorable outcome [39], yet no 
study addressing the relationship between securin 
and bladder cancer has been reported. Our previous 
study has demonstrated the expression of securin in 
TCC cells and the inhibition of securin expression by 
TrkB antibody [12]. Therefore, it was not surprising 
to find decreased expression of securin after treatment 
with the pan-Trk inhibitor lestaurtinib. Because of 
the consistent results among apoptosis, MTT assay, and 
securin inhibition, we believe that inhibition of securin 
expression is also a good indicator for TCC therapy.
In the present study, we demonstrated the potential 
of lestaurtinib for TCC therapy mediated by the inhi-
bition of survivin and securin, even on the oxaliplatin-
resistant TCC T24 cell line, resulting in apoptosis.
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